主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

北京中医药大学学报 ›› 2015, Vol. 38 ›› Issue (11): 777-780.doi: 10.3969/j.issn.1006-2157.2015.11.013

• 临床研究 • 上一篇    下一篇

益气化痰祛瘀方治疗COPD稳定期临床疗效观察*

王玮1,吴海斌2,王琦2#,张永生2,韩飞翔1,李缙婷1   

  1. 1 北京中医药大学 北京 100029;
    2 北京中医药大学东方医院
  • 收稿日期:2015-06-11 出版日期:2015-11-30 发布日期:2015-11-30
  • 通讯作者: 王琦,男,主任医师,教授,硕士生导师,主要研究方向:中医药治疗慢性肺系疾病,E-mail:13910977162@139.com
  • 作者简介:王玮,女,在读博士生
  • 基金资助:
    *北京市科委首都临床特色应用研究资助项目(No.Z121107001012147)

Clinical efficacy of TCM formula of replenishing qi and resolving phlegm and dispelling stasis on patients with stable chronic obstructive pulmonary disease*

WANG Wei1,WU Haibin2,WANG Qi2#,ZHANG Yongsheng2,HAN Feixiang1,LI Jinting1   

  1. 1 Beijing University of Chinese Medicine, Beijing 100029;
    2 Dongfang Hospital, Beijing University of Chinese Medicine
  • Received:2015-06-11 Online:2015-11-30 Published:2015-11-30

摘要: 目的 观察运用益气化痰祛瘀方治疗慢性阻塞性肺疾病(COPD)稳定期患者的临床疗效,为治疗该病探索方法。方法 选取符合纳入标准的中医证型属于肺脾肾气虚、痰瘀互阻的慢性阻塞性肺疾病稳定期患者51例,采用简单随机对照的方法将患者分为中药组26例、对照组25例。2组均给予西医常规治疗,中药组同时还口服益气化痰祛瘀方。2组疗程均为4个月。结果 中药组治疗前后对比的肺功能(FEV1)、临床症状改变值、慢性阻塞性肺疾病评分(CAT)的比较有统计学意义(P<0.05),并且和西药组对比均有统计学差异(P<0.05)。结论 益气化痰祛瘀方在改善COPD患者肺功能FEV1、症状积分、健康生活质量等方面优于西药组,并且治疗过程中安全性好,说明益气化痰祛瘀方治疗COPD具有疗效显著、控制病情稳定等特点。

关键词: 慢性阻塞性肺疾病, 益气化痰祛瘀方, 气虚血瘀痰阻, 本虚标实

Abstract: Objective To evaluate the clinical efficacy of qi-replenishing, phlegm-resolving and stasis-diapelling formula, a Chinese compound medicine, on the patients of stable stage with chronic obstructive pulmonary disease (COPD). Methods Altogether 51 COPD patients with TCM syndrome of deficiency of lung qi, spleen qi, kidney qi and phlegm-stasis obstruction were randomly divided into Chinese medication group (n=26) and control group (n=25) .The patients of the control group were treated with only routine Western medication, while those of the Chinese medication group were treated with the routine Western medication combined with TCM formula for consecutive four months. Results There were significant differences of forced expiratory volume in one second (FEV1) , changes of symptom scores and COPD assessment test (CAT) scores between after treatment and before treatment in Chinese medication group(P<0.05). Compared with control group, all the indexes mentioned above showed statistical differences in Chinese medication group(P<0.05). Conclusion The clinical efficacy and safety of Chinese formula were proved by the means of comparison of FEV1, symptom scores and CAT scores between Chinese medication group and control group.

Key words: chronic obstructive pulmonary disease, TCM formula of replenishing qi and resolving phlegm and dispelling stasis, qi deficiency and blood stasis and phlegm obstruction, deficiency in origin and excess in superficiality

中图分类号: 

  • R256.12